Malignant histiocytosis: complete remission with combination chemotherapy

Area of Science:

• Oncology
• Pediatric Hematology-Oncology
• Cancer Chemotherapy

Background:

• Malignant histiocytosis is a rare neoplastic proliferation of histiocytes.
• Effective treatment strategies for malignant histiocytosis remain an area of active research.
• This case highlights a potential therapeutic approach in pediatric oncology.

Observation:

• A 16-year-old female presented with malignant histiocytosis affecting multiple organs including lymph nodes, bone marrow, peripheral blood, liver, and spleen.
• The patient received cyclic quadruple chemotherapy using cyclophosphamide, vincristine, procarbazine, and prednisone (COPP).

Findings:

• The patient achieved a complete remission following COPP chemotherapy.
• She has remained alive and disease-free for over four years post-treatment.
• Maintenance therapy with low-dose cyclophosphamide was administered for 2.75 years.

Implications:

• The COPP regimen demonstrated significant efficacy in this case of malignant histiocytosis.
• These findings suggest that COPP chemotherapy warrants further investigation as a treatment modality for malignant histiocytosis.
• This case contributes to the understanding of long-term outcomes and treatment possibilities for this rare condition.